Zydus Cadila has received US FDA approval to market Warfarin in tablet form in different strengths of 1mg, 2mg, 2.5mg, 3mg, 4mg, 5mg, 6mg, 7.5mg and 10mg. The group plans to launch the product within a month's time. The branded sales of the product in 2005 was reported to be over $210 million. With this, the group now has a total of 14 approvals.
The group is likely to have considerable competitive advantage in this product as it will be sourcing the API from its own US FDA approved manufacturing facility at Dabhasa. The drug, an anti-coagulant, falls in the cardiovascular segment.